ToolGen Inc is a Korea-based company principally engaged in gene editing research and development and related businesses. The Companyâ€™s main products include patent monetization business, gene editing therapeutics, and functional seeds. The Company also operates customized gene-editing tool development services and gene analysis services. The Company sells its products in domestic and overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-26	₩41,600.00	-5.13%	31,910
26-06-25	₩43,850.00	-8.84%	38,768
26-06-24	₩48,100.00	+7.01%	54,531
26-06-23	₩44,950.00	-1.10%	57,098
26-06-22	₩45,450.00	+0.33%	25,487

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 2026-06-26			5-day change	1st Jan Change
41,600.00 ^KRW	-5.13%		-9.47%	-29.01%

02-12	ToolGen Incorporated Appoints Dave Boncheun Koo as New Chief Legal Officer and Executive Vice President	CI
11-24	Toolgen Inc. and Geneditbio Limited Enter Strategic Cross- License Agreement	CI

Market Cap	374B 244M 214M 197M 185M 346M 22.99B 353M 2.37B 919M 11.35B 915M 895M 39.52B	P/E 2024	49.3x	P/E 2025	-13.8x
Enterprise Value	346B 225M 198M 182M 171M 320M 21.24B 326M 2.19B 849M 10.48B 846M 827M 36.52B	EV / Sales 2024	328x	EV / Sales 2025	380x
Free-Float	80.72%	Yield 2024 *	-	Yield 2025	-

02-12	ToolGen Incorporated Appoints Dave Boncheun Koo as New Chief Legal Officer and Executive Vice President	CI
11-24	Toolgen Inc. and Geneditbio Limited Enter Strategic Cross- License Agreement	CI
11-19	Toolgen completes U.S. patent registration for core CRISPR Cas9 RNP technology; files U.S. lawsuit related to Casgevy®	RE
23-11-01	ToolGen Incorporated announced that it has received KRW 33 billion in funding	CI
23-10-30	ToolGen Incorporated announced that it expects to receive KRW 33 billion in funding	CI
23-04-18	Toolgen Leads Development of Numerous Cutting-Edge Genome Editing Techniques	CI
23-03-23	ToolGen Incorporated Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-09-19	ToolGen Incorporated(KOSDAQ:A199800) added to S&P Global BMI Index	CI
22-06-15	MCureX Therapeutics, Inc. Signs Contract for Joint Research with Toolgen, Inc	CI
21-12-06	ToolGen Incorporated has completed an IPO in the amount of KRW 70 billion.	CI
21-09-14	ToolGen Incorporated has filed an IPO.	CI
20-12-20	ToolGen Incorporated announced that it has received KRW 10.0000004 billion in funding from Genexine, Inc.	CI
20-12-10	ToolGen Incorporated announced that it expects to receive KRW 10.0000004 billion in funding from Genexine, Inc.	CI

24-12-05	ToolGen and PlantArcBio Forge Strategic Collaboration to Develop GeneEdited, Herbicide Tolerant Soybeans for Global Markets	AQ
24-04-17	The 2023 Pharmaceutical Patent Review	AQ
23-11-16	DCC Insights Issue 19	AQ
23-08-15	ToolGen Incorporated v Fisher (No 2) – Lessons In Entitlement To Priority From The Australian Federal Court	AQ

ToolGen Incorporated Stock

Stocks

A199800

KR7199800004

Biotechnology & Medical Research

Valuation: ToolGen Incorporated

Chart: ToolGen Incorporated

Latest news : ToolGen Incorporated

Press Releases: ToolGen Incorporated

Quotes and Performance

Course Extremes

Managers and Directors: ToolGen Incorporated

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-5.13%
1 week	-9.47%
Current month	-13.51%
1 month	-35.70%
3 months	-14.75%
6 months	-20.00%
Current year	-29.01%

1 week	40,450	49,200
1 month	40,450	70,400
Current year	40,450	142,000
1 year	26,650	142,000
3 years	26,100	142,000
5 years	26,100	166,500
10 years	22,100	173,700

Manager	Title	Age	Since
Jong-Sang Yoo CEO	Chief Executive Officer	55	2025-03-27
Jang-Hyub Ha DFI	Director of Finance/CFO	49	-
Baek-Seung Lee CTO	Chief Tech/Sci/R&D Officer	56	-

Director	Title	Age	Since
Jin-Soo Kim BRD	Director/Board Member	62	1999-10-07
Seong-Joon Hong BRD	Director/Board Member	61	2021-02-28
Jong-Sang Yoo BRD	Director/Board Member	55	2025-03-27

Date	Insider	Type	Main position	Quantity	% Market Cap.
25-01-05	Jin-Soo Kim	Others	Founder	680,144	7.9584%
24-08-06	Lee Jaeyoung	Fiscal year		4,000	0.0504%
24-08-06	Ji-hak Han	Fiscal year		1,670	0.0210%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TOOLGEN INCORPORATED	-5.13%	-9.47%	+39.13%	-3.70%	256M
LONZA GROUP AG	-0.48%	+8.75%	-5.51%	+0.91%	46.36B
REVOLUTION MEDICINES, INC.	+2.19%	+11.71%	+374.04%	+613.48%	37.88B
IQVIA HOLDINGS INC.	+2.53%	+13.93%	+20.43%	-10.71%	31.12B
BEONE MEDICINES AG	+1.65%	+3.61%	+4.78%	+56.12%	30.61B
CELLTRION, INC.	-4.16%	-4.44%	+8.53%	+16.06%	24.69B
ASCENDIS PHARMA A/S	-0.32%	+12.96%	-	-	16.25B
MEDPACE HOLDINGS, INC.	+1.37%	+14.53%	+69.40%	+135.94%	14.85B
EUROFINS SCIENTIFIC SE	+1.00%	+9.67%	+14.90%	+21.88%	13.58B
IONIS PHARMACEUTICALS, INC.	+3.63%	+9.53%	+102.95%	+104.79%	12.95B
Average	+0.23%	+6.22%	+69.85%	+103.86%	22.85B
Weighted average by Cap.	+0.71%	+7.64%	+82.34%	+135.34%

	2024	2025
Net sales	891M 580K 510K 470K 440K 824K 54.73M 841K 5.65M 2.19M 27.02M 2.18M 2.13M 94.1M	1.31B 850K 747K 688K 645K 1.21M 80.26M 1.23M 8.29M 3.21M 39.62M 3.2M 3.13M 138M
Net income	6.23B 4.06M 3.56M 3.28M 3.08M 5.76M 383M 5.88M 39.55M 15.3M 189M 15.24M 14.91M 658M	-36.76B -23.93M -21.03M -19.37M -18.16M -34.01M -2.26B -34.71M -233M -90.26M -1.11B -89.93M -87.98M -3.88B
Net Debt	-34.94B -22.75M -19.99M -18.41M -17.26M -32.32M -2.15B -32.99M -222M -85.78M -1.06B -85.47M -83.62M -3.69B	-28.43B -18.51M -16.26M -14.98M -14.05M -26.3M -1.75B -26.84M -180M -69.8M -862M -69.54M -68.04M -3B